Shalina Gupta-Burt, MD
Radiation Oncology · North Kansas City, MONPI 1639140288
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,450 of the $9,413 with a category attached, or 68.5%. Novocure Inc. accounts for 95.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $3,964 and has fallen 99.6% since, to $18 in 2025.
Across 48 payments — averaging $196.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$9K
- AstraZeneca$142
- Puma Biotechnology, Inc.$106
- Merck$39
- E.r. Squibb & Sons, L.L.C.$25
- Johnson & Johnson$24
- plus $117 from 7 others
Across 77 payments — averaging $5404.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$398K
- Siemens Medical Solutions USA, Inc.$17K
- Novocure Inc.$534
What the payments were for
- Speaking & faculty fees$6,45069%
- Travel & lodging$1251%
- Food & beverage$2,83830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 32 | $8,960 |
| AstraZeneca | 2 | $142 |
| Puma Biotechnology, Inc. | 1 | $106 |
| Merck | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Johnson & Johnson | 2 | $24 |
| Amgen | 1 | $20 |
| Incyte Corporation | 1 | $19 |
| Gilead | 1 | $18 |
| Novartis | 1 | $18 |
| AbbVie | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,413 in reported general payments places this provider in the 85th percentile of 123 radiation oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 29 | $725 |
| Lidocaine Hcl ViscousLidocaine Hcl | 21 | $354 |
| Lorazepam | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in North Kansas City
- John ParkNorth Kansas City$1K
- Clifford RobinsonSaint Louis$817K
- Carlos PerezSpringfield$103K
- Pamela SamsonSaint Louis$95K
- Jeffrey BradleySaint Louis$75K
- Christopher SpencerRolla$70K
- Matthew SprakerSaint Louis$61K
- Lauren HenkeSaint Louis$45K
- Jeff MichalskiSaint Louis$44K
- Gregory BiedermannColumbia$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.